Cannabidiol - TALENT Biotech

Drug Profile

Cannabidiol - TALENT Biotech

Latest Information Update: 07 Mar 2017

Price : $50

At a glance

  • Originator TALENT Biotech
  • Class Analgesics; Antiepileptic drugs; Antipsychotics; Anxiolytics; Cannabinoids; Muscle relaxants; Neuroprotectants; Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 antagonists; Serotonin 1 receptor agonists; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Phase II Graft-versus-host disease

Most Recent Events

  • 07 Mar 2017 Chemical structure information added
  • 02 Mar 2017 Talent Biotech completes pilot studies in Graft-versus-host disease (Treatment)
  • 22 Feb 2017 Preliminary efficacy data from a phase II trial in Graft-versus-host disease released by Kalytera Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top